Vir & Biogen to manufacture antibodies to potentially treat Covid-19

Vir Biotechnology and Biogen are teaming up for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of Covid-19.

Due the to the urgency of the situation, the companies have already started work while a Clinical Development and Manufacturing Agreement is being negotiated.

Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Vir’s proprietary antibodies.

“These exceptional circumstances presented by the threat of Covid-19 require that we work with great urgency in the interest of the public good,” said George Scangos, CEO of Vir.

Vir has identified several monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS infection.

The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news